and low density lipoproteins (LDL) from human normolipemic plasma, and the VLDL, the intermediate density lipoprotein (IDL), and LDL from patients with Type III hyperlipoproteinemic plasma were tested for their abilities to suppress the activity of 3-hydroxy-3-methylglutaryl-Coenzyme A (HMGCoA) reductase in cultured human fibroblasts from normal subjects and a Type III patient. Regulation of cholesterol synthesis in the fibroblasts of a patient with Type III hyperlipoproteinemia appears to be normal. VLDL from normal subjects, isolated by angle head ultracentrifugation (d < 1.006) or by gel filtration on BioGel A-5m, were about 5 times less effective than LDL in suppressing HMG-CoA reductase activity, based on protein content, in agreement with previous reports with normal fibroblasts. Zonal centrifugation of normal VLDL isolated by both methods showed that the VLDL contained IDL. Normal VLDL from the angle head rotor, refractionated by the zonal method, had little, if any, ability to suppress the HMGCoA reductase activity in either normal or Type III fibroblasts. VLDL, IDL, and LDL fractionated by zonal ultracentrifugation from Type III plasma gave halfmaximum inhibition at 0.2-0.5 ,g of protein/ml, indistinguishable from the suppression caused by A preliminary report of this work has appeared in abstract form (1976, Circulation. 54: 11-55 normal LDL. Type III VLDL did not suppress HMGCoA reductase in mutant LDL receptor-negative fibroblasts. Zonally isolated VLDL obtained from one Type IV and one Type V patient gave half-maximal suppression at 5 and 0.5 ,g of protein/ml, respectively. Molecular diameters and apoprotein compositions of the zonally isolated normal and Type III VLDL were similar; the major difference in composition was that Type III VLDL contained more cholesteryl esters and less triglyceride than did normal VLDL. The compositions and diameters of the Type IV and Type V VLDL were similar to normal VLDL. These findings show that the basic defect in Type III hyperlipoproteinemia is qualitatively different from the cellular defect found in familial hypercholesterolemia, since the regulation of HMG-CoA reductase activity is normal in Type III fibroblasts. The metabolic defect in hypertriglyceridemia is related to the triglyceriderich lipoproteins which, free of other lipoproteins, have an enhanced ability to interact with cultured fibroblasts to regulate HMG-CoA reductase activity. These studies suggest that, in hypertriglyceridemia, there is a mechanism for direct cellular catabolism of VLDL which is not functional for normal VLDL.
A B S T R A C T Very low density lipoproteins (VLDL)
and low density lipoproteins (LDL) from human normolipemic plasma, and the VLDL, the intermediate density lipoprotein (IDL), and LDL from patients with Type III hyperlipoproteinemic plasma were tested for their abilities to suppress the activity of 3-hydroxy-3-methylglutaryl-Coenzyme A (HMGCoA) reductase in cultured human fibroblasts from normal subjects and a Type III patient. Regulation of cholesterol synthesis in the fibroblasts of a patient with Type III hyperlipoproteinemia appears to be normal. VLDL from normal subjects, isolated by angle head ultracentrifugation (d < 1.006) or by gel filtration on BioGel A-5m, were about 5 times less effective than LDL in suppressing HMG-CoA reductase activity, based on protein content, in agreement with previous reports with normal fibroblasts. Zonal centrifugation of normal VLDL isolated by both methods showed that the VLDL contained IDL. Normal VLDL from the angle head rotor, refractionated by the zonal method, had little, if any, ability to suppress the HMGCoA reductase activity in either normal or Type III fibroblasts. VLDL, IDL, and LDL fractionated by zonal ultracentrifugation from Type III plasma gave halfmaximum inhibition at 0.2-0.5 ,g of protein/ml, indistinguishable from the suppression caused by A preliminary report of this work has appeared in abstract form (1976, Circulation. 54: 11-55) .
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Received for publication 31 December 1976 and in revised form 21 September 1977. normal LDL. Type III VLDL did not suppress HMGCoA reductase in mutant LDL receptor-negative fibroblasts. Zonally isolated VLDL obtained from one Type IV and one Type V patient gave half-maximal suppression at 5 and 0.5 ,g of protein/ml, respectively. Molecular diameters and apoprotein compositions of the zonally isolated normal and Type III VLDL were similar; the major difference in composition was that Type III VLDL contained more cholesteryl esters and less triglyceride than did normal VLDL. The compositions and diameters of the Type IV and Type V VLDL were similar to normal VLDL. These findings show that the basic defect in Type III hyperlipoproteinemia is qualitatively different from the cellular defect found in familial hypercholesterolemia, since the regulation of HMG-CoA reductase activity is normal in Type III fibroblasts. The metabolic defect in hypertriglyceridemia is related to the triglyceriderich lipoproteins which, free of other lipoproteins, have an enhanced ability to interact with cultured fibroblasts to regulate HMG-CoA reductase activity. These studies suggest that, in hypertriglyceridemia, there is a mechanism for direct cellular catabolism of VLDL which is not functional for normal VLDL.
INTRODUCTION
In Type III hyperlipoproteinemia (broad ,3-disease, or dysbetalipoproteinemia), plasma cholesterol and triglyceride levels are typically increased (1) For experiments, confluent cell monolayers were dissociated from stock plates with trypsin (100 Ag/ml; Grand Island Biological Co.) and the cells combined. Approximately 105 cells were then dispersed in 5 ml of complete medium into 60-mm plastic tissue culture dishes and placed in a 37°C humidified incubator under 5% CO2 for this and subsequent incubations of cells. The medium was changed after 3 days. When the cells were 75-100% confluent (5-7 days), the medium was removed; the cells were washed with 3 ml of saline and were placed on 3 ml of medium containing 5% human lipoprotein-deficient serum (LPDS) for 24 h to allow HMG-CoA reductase activity to increase to unsuppressed levels. Measured quantities of lipoproteins were then added to duplicate dishes for 16 h. The medium was then removed, the cell monolayers washed twice at room temperature 2 ml of saline, an.d the cells removed with a rubber policeman into 2.0 ml of 0.15 M NaCl, 50 mM Tris-HCl, pH 7.4 . The cells were sedimented by centrifugation, the supernate was discarded, and the cell pellets stored at -80°C.
HMG-CoA reductase assay. HMG-CoA reductase activities were determined by a modification of the method of Brown et al. (5) . Thawed cell pellets were incubated for 10 min at 37°C with 0.1 ml of 50 mM K2HPO4, pH 7.4, containing 5 mM dithiothreitol, 1 mM EDTA, and 0.25% Kyro EOB (Proctor & Gamble, Cincinnati, Ohio). After centrifugation for 5 min at 5,000 rpm at room temperature, the clear supernates were assayed in duplicate for HMG-CoA reductase activity. Cell extracts (20 ,ul 15 ,lI of the acidified reaction mixture, in 5-,tl aliquots, was streaked on silica thin-layer chromatograms. The chromatograms were air-dried and developed in acetonebenzene (1:1, vol/vol) until the solvent front had moved 5.5 cm above the origin. Areas of the chromatogram containing mevalonolactone (Rf 0.63) and residual HMG-CoA (origin) were counted with Triton X-100:toluene scintillation fluid (10) . To calculate the picomoles of mevalonate formed during the incubations, the fraction of total radioactivity which appeared in the mevalonolactone region was multiplied by the picomoles of HMG-CoA initially present in the assay. For figures, each HMG-CoA reductase activity data point is the average of values from duplicate dishes; the variation between duplicate values in each experiment is stated in each figure legend. Protein content of extracts was determined by the method of Lowry et al. (11) , with bovine serum albumin as a standard.
Lipoproteins and lipoprotein-deficient serum. Normal lipoprotein fractions and LPDS were isolated from the plasma of fasting adult normolipemic males. Diagnoses of hyperlipoproteinemia types were based on commonly used criteria (1) . Secondary causes of hyperlipoproteinemia were excluded for each patient from whom lipoproteins were obtained. None of the patients was on any special diet or medication at the time plasma was taken for lipoprotein isolation. Type III patients M. A. and W. M. had been on no special diet or medication for 1 mo before plasma was obtained. Type III patient J. H. and Type IV patient Y. K. had never received lipid-lowering drugs. Type V patient M. V. had received Atromid S and was on a restricted carbohydrate diet. Blood was collected in 0.1% EDTA from fasting subjects; erythrocytes were removed by low-speed centrifugation. To prepare LPDS, lipoproteins were removed by flotation at d 1.21 (KBr) in a Beckman preparative ultracentrifuge (L3-50) using a 60 Ti rotor (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.) at 45,000 rpm at 14WC for 60 h. LPDS was dialyzed against two changes of 150 vol of 0.15 M NaCl containing 50 mM Tris-HCl, pH 7.4, and 0.3 mM EDTA at 4°C for 36-48 h. After clotting with thrombin (4), LPDS was sterilized by filtration through a 0.2-gm filter unit (Nalge Co., Rochester, N. Y.) and stored at -20°C. Normal VLDL and LDL for the experiment in Fig. 2 were isolated from the lipoprotein fraction, obtained from the ultracentrifugation of plasma at d = 1.21, by chromatography over Bio-Gel A-5m, 200-400 mesh, 6 x 60 cm (BioRad Laboratories, Richmond, Calif.) (12) . All other lipoprotein fractions were isolated from plasma according to standard techniques by sequential flotation in a 60 Ti rotor at 45,000 rpm and 14°C for 18-22 h (13). VLDL were isolated in a single centrifugation without adjusting the density of plasma (d < 1.006); intermediate density lipoproteins (IDL) were isolated at d = 1.006-1.020, and LDL at d = 1.020-1.063. Each lipoprotein class was further purified by rate zonal ultracentrifugation in a Beckman Ti-14 zonal rotor. A linear gradient in the density range of 1.000-1.300 (NaBr) was used for ultracentrifugation at 15°C and 42,000 rpm for 140 min (14) . All lipoproteins were concentrated by ultrafiltration at <7 psi N2 at 4°C in an Amicon Cell (model 8MC) fitted with an XM-100 A membrane (Amicon Corp., Scientific Systems Div., Lexington, Mass.). Lipoprotein fractions were dialyzed at 4°C against two changes of 150 vol of 0.15 M NaCl containing 50 mM Tris-HCl, pH 7.5, and 0.3 mM EDTA, sterilized by filtration, and stored at 4°C. Cholesterol and triglyceride contents of the lipoprotein fraction were determined in the Core Laboratory of the Baylor Lipid Research Clinic (15) .
Free and total cholesterol were determined by an enzymatic colorimetric method (16) . The difference between free and total cholesterol was multiplied by a factor of 1.68 to calculate cholesteryl ester content. Lipid phosphorus was determined by the method of Bartlett (17) . A factor of 25 was used to convert lipid phosphorus into phospholipid concentration.
Total protein contents of the lipoproteins were determined by a modification of the Lowry method; sodium dodecyl sulfate, at a final concentration of 0. 1%, was included to prevent interference by opalescence and light scattering (18) . The major protein component of VLDL and LDL, apoB, was determined as the difference between the total protein and the protein soluble in 4.2 tetramethylurea (19) . Soluble apoprotein comiiposition was determined after delipidation with ether:ethanol, 3:1 (vol/vol). The apoproteins were separated by electrophoresis on 7.5% polyacrylamide gels containing 8 M urea, stained with Amido-Schwartz, and quantitated by scanning densitometry (19) .
Diameters of the lipoproteins were determninied by electron microscopy after negative staininlg with phophotungstic acid (20) .
RESULTS
The zonal ultracentrifugal lipoproteini profile in Type III plasma is abnormal (Fig. 1 A) (Fig. 1 B) . However, Type III VLDL in the initial 100-ml effluent from the zonal rotor contained only pre-,B migrating lipoproteins on Geon Pevikon electrophoresis (9 HMIG-CoA reductase activity; approximately 10 jig of protein/mil of each gave complete suppression (Fig. 2) (Fig. 3) . VLDL from a third patient ("A. L.) with Type III was also inhibitory (Fig. 7) . Thus, the fuinctional abnormality was fouind in all three of the Type III patients available for study.
The (Fig. 4 A) or by gel filtration (Fig. 4 VLDL isolated by zonal centrifugation from the plasma of five fasting normolipemic males were studied with four normal cell lines. In each experiment, zonally isolated normal VLDL had little, if any, ability to suppress HMG-CoA reductase activity in the range of cholesterol or protein concentrations that gave complete suppression by LDL (Fig. 3) (Fig. 6 ). Normal VLDL had no effect in the mutant cells.
VLDL were prepared by zonal centrifugation from the plasma of two patients with other types of hypertriglyceridemia (Fig. 7) . The VLDL from a Type V patient were as suppressive as normal LDL, with half-maximal suppression occurring at approximately 0.5 ,ug of protein/ml. The VLDL from a Type IV individual also suppressed, with half-maximal suppression at about 5 ,u g of protein/ml. The VLDL contained no IDL yet were inhibitory. The fibroblasts may be a common characteristic of hypertriglyceridemia. The chemical compositions of the lipoproteins studied are given in Table I . The apoprotein contents of the normal VLDL and the Type III VLDL were similar. The normal VLDL protein was 58% apoB, 9% arginine-rich apoprotein, and 33% apoC (the small molecular weight apoproteins of VLDL), whereas the Type III VLDL contained 62% apoB, 11% arginine-rich apoprotein, and 27% apoC. The Type III VLDL were approximately 30% cholesteryl ester by weight, compared with the 6-14% cholesteryl ester content of normal VLDL. Type III VLDL contained less triglyceride than normal VLDL, 31-42% and 50-62%, respectively. The lipid and apoprotein compositions of the Types IV and V VLDL were similar to those of normal VLDL. The ranges of diameters of all of the hypertriglyceridemic VLDL were the same as those of normal VLDL, as determined by negative staining. There are no differences in the mean diameters of the hypertriglyceridemic and normal VLDL that could account for the differences in effects on HMG-CoA reductase activity. Fig. 2 . Normal VLDL isolated in an angle head rotor or by gel filtration (Fig. 2) suppressed HMG-CoA reductase, as previously reported by others (4, 5) ; however, zonal ultracentrifugation analysis indicated that IDL was present in this fraction (Fig. 4) Our studies document the abnormal ability of triglyceride-rich lipoproteins present in the plasmas of patients with Types III, IV, and V hyperlipoproteinemias to suppress the activity of HMG-CoA reductase of cultured fibroblasts. Moreover, there appear to be similar mechanisms involved in the suppressioni by LDL and by the VLDL from hypertriglyceridemic patients. Binding to the LDL cell surface receptor of normal fibroblasts is thought to involve apoB (21) or the arginine-rich protein (22) . These apoproteins are present in normal VLDL isolated both by the zonal method and by conventional techniques (14, 23, 24) . We founid that the argininerich apoprotein content of zonally isolated normal and Type III VLDL were similar, in contrast to the observations of Havel and Kane (24) and Utermann et al. (25) that the amount of arginine-rich apoprotein is elevated two-to threefold in VLDL from Type III patients. These differences may be due to differences in VLDL isolation used in the two laboratories. The inability of normal VLDL, which contain both apoB and the arginine-rich protein, to suppress remains to be explained. There appears to be no single determinant, such as apoB, cholesterol or cholesteryl ester content, or lipoprotein diameter, which produces an obligatory interaction that results in suppression. The lipid and apoprotein components of zonally isolated normal VLDL and VLDL from the plasmas of subjects with hyperlipoproteinemia are qualitatively the same (Table I) . Within the constraints of the present analytical methods, the differences in apoprotein content of the various VLDL isolated by the zonal method cannot be considered significant. The The different clinical manifestations of these disorders and the heterogeneity of the VLDL (26) remain as sources of spectulation about the cellular process by which these various lipoproteins effect suppression of HNIG-CoA reductase. The abnormal suppressiveness of hypertriglyceridemic VLDL may be due to chylomicron remnants, known to be present in VLDL from plasma of subjects with Type III and Type IV hyperlipoproteinemia (27) . Although the present study adds strong confirmation to the observation that hypertriglyceridemia and vascular disease are in some way linked, the mechanisms of this relationship are still unknown. Future studies are required to define further these important, complex mechanisms involved in the regulation of cellular cholesterol synthesis.
In summary, these findings show that the basic defect in Type III hyperlipoproteinemia is qualitatively differenit from the cellular defect found in familial hypercholesterolemia, since the regulation of HMG-CoA reductase activity is normal in Type III fibroblasts. The metabolic defect in hypertriglyceridemia is related to the triglyceride-rich lipoproteins which, free of other lipoproteins, have an enhanced ability to interact with cultured fibroblasts to regulate HMG-CoA reductase activity. These studies suggest that, in hypertriglyceridemia, there is a mechanism for direct cellular catabolism of VLDL which is not functional for normal VLDL.
